Leerink Partnrs Comments on Teladoc Health Q1 Earnings

Teladoc Health, Inc. (NYSE:TDOC - Free Report) - Equities researchers at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Teladoc Health in a research report issued to clients and investors on Wednesday, October 30th. Leerink Partnrs analyst M. Cherny anticipates that the health services provider will earn ($0.31) per share for the quarter. The consensus estimate for Teladoc Health's current full-year earnings is ($1.18) per share. Leerink Partnrs also issued estimates for Teladoc Health's Q2 2025 earnings at ($0.26) EPS and Q3 2025 earnings at ($0.29) EPS.

Teladoc Health (NYSE:TDOC - Get Free Report) last released its earnings results on Wednesday, October 30th. The health services provider reported ($0.19) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.10. Teladoc Health had a negative net margin of 37.91% and a negative return on equity of 9.40%. The business had revenue of $640.51 million during the quarter, compared to analysts' expectations of $630.50 million.

TDOC has been the subject of a number of other reports. Jefferies Financial Group upped their target price on Teladoc Health from $8.00 to $10.00 and gave the company a "hold" rating in a research note on Tuesday, September 17th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of Teladoc Health from $10.00 to $12.00 and gave the company a "hold" rating in a research note on Friday. Oppenheimer decreased their target price on shares of Teladoc Health from $21.00 to $17.00 and set an "outperform" rating on the stock in a research report on Thursday, August 1st. TD Cowen lowered their target price on shares of Teladoc Health from $9.00 to $8.00 and set a "hold" rating on the stock in a research note on Thursday. Finally, DA Davidson cut their price target on shares of Teladoc Health from $12.00 to $8.00 and set a "neutral" rating for the company in a research note on Thursday, August 1st. Fourteen equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to MarketBeat, the company has an average rating of "Hold" and an average price target of $11.97.

Teladoc Health Stock Performance

Teladoc Health stock traded up $0.21 during trading hours on Friday, hitting $9.22. The stock had a trading volume of 6,591,671 shares, compared to its average volume of 5,475,505. Teladoc Health has a fifty-two week low of $6.76 and a fifty-two week high of $22.54. The company has a market cap of $1.58 billion, a PE ratio of -1.60 and a beta of 0.91. The company has a 50-day moving average of $8.48 and a two-hundred day moving average of $9.69. The company has a quick ratio of 1.62, a current ratio of 1.66 and a debt-to-equity ratio of 0.66.

Insider Transactions at Teladoc Health

In other Teladoc Health news, CMO Stephany Verstraete sold 15,000 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $7.60, for a total transaction of $114,000.00. Following the sale, the chief marketing officer now owns 45,158 shares of the company's stock, valued at $343,200.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other news, CMO Stephany Verstraete sold 15,000 shares of the company's stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $7.60, for a total transaction of $114,000.00. Following the transaction, the chief marketing officer now directly owns 45,158 shares in the company, valued at approximately $343,200.80. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Thomas Mckinley purchased 7,000 shares of the stock in a transaction that occurred on Tuesday, August 6th. The stock was bought at an average cost of $7.57 per share, with a total value of $52,990.00. Following the acquisition, the director now owns 31,077 shares of the company's stock, valued at $235,252.89. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 36,588 shares of company stock worth $268,831. Insiders own 0.95% of the company's stock.

Hedge Funds Weigh In On Teladoc Health

Large investors have recently made changes to their positions in the company. Signaturefd LLC boosted its position in shares of Teladoc Health by 148.7% in the 2nd quarter. Signaturefd LLC now owns 2,868 shares of the health services provider's stock worth $28,000 after purchasing an additional 1,715 shares during the last quarter. International Assets Investment Management LLC acquired a new position in shares of Teladoc Health during the 2nd quarter worth about $29,000. Blue Trust Inc. grew its position in shares of Teladoc Health by 84.5% during the 3rd quarter. Blue Trust Inc. now owns 4,048 shares of the health services provider's stock worth $40,000 after buying an additional 1,854 shares during the period. Doheny Asset Management CA bought a new stake in shares of Teladoc Health in the 2nd quarter valued at about $46,000. Finally, SageView Advisory Group LLC acquired a new stake in shares of Teladoc Health in the 1st quarter valued at approximately $48,000. Institutional investors and hedge funds own 76.82% of the company's stock.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.